Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: A 2-year study

G. Y. Tseng, H. J. Lin, C. T. Fang, H. B. Yang, G. C. Tseng, P. C. Wang, T. L. Hung, Y. C. Deng, Y. T. Cheng, C. H. Huang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: The role of Helicobacter pylori in the pathogenesis of peptic ulcer disease in patients with uraemia remains unclear. Aim: To evaluate the long-term effect of H. pylori eradication in these patients. Methods: Uraemic and non-uraemic patients with peptic ulcer were enrolled in this study. Patients having history of non-steroidal anti-inflammatory drugs use or cardiovascular disease that need aspirin use were excluded. After confirmation of H. pylori infection, they received a triple therapy and were followed up for 2 years. Results: Between September 1999 and December 2005, 34 patients (41%) of the end-stage renal disease [H. pylori (+) group] and 67 (84%) of the non-uraemic patients with peptic ulcer disease (PU group) received anti-H. pylori therapy. After triple therapy, 32 (94%) from the end-stage renal disease group and 64 (96%) from the peptic ulcer group obtained successful eradication. During the 2-year follow-up, three patients in the end-stage renal disease group were excluded because of the presence of cardiovascular disease and aspirin use in two cases and died of heart failure in one case; two patients in peptic ulcer group refused follow-up. Finally, 29 uraemic and 62 non-uraemic patients had achieved the follow-up. Recurrence of peptic ulcer was more in the end-stage renal disease group than in the peptic ulcer group with intention-to-treat analysis (eight of 32, 25% vs. two of 64, 3%, P = 0.001, OR: 10.0, 95% CI: 1.979-50.540) or per-protocol analysis (eight of 29, 28% vs. two of 62, 3%, P <0.001, OR: 11.4, 95% CI: 2.245-58.168). Conclusions: Peptic ulcer recurrence after H. pylori eradication is higher in end-stage renal disease patients with peptic ulcer than in peptic ulcer patients without renal disease. Factors aside from H. pylori play an important role in peptic ulcer recurrence in end-stage renal disease patients.

Original languageEnglish
Pages (from-to)925-933
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume26
Issue number6
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Peptic Ulcer
varespladib methyl
Helicobacter pylori
Recurrence
Chronic Kidney Failure
Aspirin
Cardiovascular Diseases
Intention to Treat Analysis
Uremia
Helicobacter Infections
Anti-Inflammatory Agents
Therapeutics
Heart Failure
Kidney

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication : A 2-year study. / Tseng, G. Y.; Lin, H. J.; Fang, C. T.; Yang, H. B.; Tseng, G. C.; Wang, P. C.; Hung, T. L.; Deng, Y. C.; Cheng, Y. T.; Huang, C. H.

In: Alimentary Pharmacology and Therapeutics, Vol. 26, No. 6, 09.2007, p. 925-933.

Research output: Contribution to journalArticle

Tseng, G. Y. ; Lin, H. J. ; Fang, C. T. ; Yang, H. B. ; Tseng, G. C. ; Wang, P. C. ; Hung, T. L. ; Deng, Y. C. ; Cheng, Y. T. ; Huang, C. H. / Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication : A 2-year study. In: Alimentary Pharmacology and Therapeutics. 2007 ; Vol. 26, No. 6. pp. 925-933.
@article{be17cf45eccb43938e5c579145044d72,
title = "Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: A 2-year study",
abstract = "Background: The role of Helicobacter pylori in the pathogenesis of peptic ulcer disease in patients with uraemia remains unclear. Aim: To evaluate the long-term effect of H. pylori eradication in these patients. Methods: Uraemic and non-uraemic patients with peptic ulcer were enrolled in this study. Patients having history of non-steroidal anti-inflammatory drugs use or cardiovascular disease that need aspirin use were excluded. After confirmation of H. pylori infection, they received a triple therapy and were followed up for 2 years. Results: Between September 1999 and December 2005, 34 patients (41{\%}) of the end-stage renal disease [H. pylori (+) group] and 67 (84{\%}) of the non-uraemic patients with peptic ulcer disease (PU group) received anti-H. pylori therapy. After triple therapy, 32 (94{\%}) from the end-stage renal disease group and 64 (96{\%}) from the peptic ulcer group obtained successful eradication. During the 2-year follow-up, three patients in the end-stage renal disease group were excluded because of the presence of cardiovascular disease and aspirin use in two cases and died of heart failure in one case; two patients in peptic ulcer group refused follow-up. Finally, 29 uraemic and 62 non-uraemic patients had achieved the follow-up. Recurrence of peptic ulcer was more in the end-stage renal disease group than in the peptic ulcer group with intention-to-treat analysis (eight of 32, 25{\%} vs. two of 64, 3{\%}, P = 0.001, OR: 10.0, 95{\%} CI: 1.979-50.540) or per-protocol analysis (eight of 29, 28{\%} vs. two of 62, 3{\%}, P <0.001, OR: 11.4, 95{\%} CI: 2.245-58.168). Conclusions: Peptic ulcer recurrence after H. pylori eradication is higher in end-stage renal disease patients with peptic ulcer than in peptic ulcer patients without renal disease. Factors aside from H. pylori play an important role in peptic ulcer recurrence in end-stage renal disease patients.",
author = "Tseng, {G. Y.} and Lin, {H. J.} and Fang, {C. T.} and Yang, {H. B.} and Tseng, {G. C.} and Wang, {P. C.} and Hung, {T. L.} and Deng, {Y. C.} and Cheng, {Y. T.} and Huang, {C. H.}",
year = "2007",
month = "9",
doi = "10.1111/j.1365-2036.2007.03438.x",
language = "English",
volume = "26",
pages = "925--933",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication

T2 - A 2-year study

AU - Tseng, G. Y.

AU - Lin, H. J.

AU - Fang, C. T.

AU - Yang, H. B.

AU - Tseng, G. C.

AU - Wang, P. C.

AU - Hung, T. L.

AU - Deng, Y. C.

AU - Cheng, Y. T.

AU - Huang, C. H.

PY - 2007/9

Y1 - 2007/9

N2 - Background: The role of Helicobacter pylori in the pathogenesis of peptic ulcer disease in patients with uraemia remains unclear. Aim: To evaluate the long-term effect of H. pylori eradication in these patients. Methods: Uraemic and non-uraemic patients with peptic ulcer were enrolled in this study. Patients having history of non-steroidal anti-inflammatory drugs use or cardiovascular disease that need aspirin use were excluded. After confirmation of H. pylori infection, they received a triple therapy and were followed up for 2 years. Results: Between September 1999 and December 2005, 34 patients (41%) of the end-stage renal disease [H. pylori (+) group] and 67 (84%) of the non-uraemic patients with peptic ulcer disease (PU group) received anti-H. pylori therapy. After triple therapy, 32 (94%) from the end-stage renal disease group and 64 (96%) from the peptic ulcer group obtained successful eradication. During the 2-year follow-up, three patients in the end-stage renal disease group were excluded because of the presence of cardiovascular disease and aspirin use in two cases and died of heart failure in one case; two patients in peptic ulcer group refused follow-up. Finally, 29 uraemic and 62 non-uraemic patients had achieved the follow-up. Recurrence of peptic ulcer was more in the end-stage renal disease group than in the peptic ulcer group with intention-to-treat analysis (eight of 32, 25% vs. two of 64, 3%, P = 0.001, OR: 10.0, 95% CI: 1.979-50.540) or per-protocol analysis (eight of 29, 28% vs. two of 62, 3%, P <0.001, OR: 11.4, 95% CI: 2.245-58.168). Conclusions: Peptic ulcer recurrence after H. pylori eradication is higher in end-stage renal disease patients with peptic ulcer than in peptic ulcer patients without renal disease. Factors aside from H. pylori play an important role in peptic ulcer recurrence in end-stage renal disease patients.

AB - Background: The role of Helicobacter pylori in the pathogenesis of peptic ulcer disease in patients with uraemia remains unclear. Aim: To evaluate the long-term effect of H. pylori eradication in these patients. Methods: Uraemic and non-uraemic patients with peptic ulcer were enrolled in this study. Patients having history of non-steroidal anti-inflammatory drugs use or cardiovascular disease that need aspirin use were excluded. After confirmation of H. pylori infection, they received a triple therapy and were followed up for 2 years. Results: Between September 1999 and December 2005, 34 patients (41%) of the end-stage renal disease [H. pylori (+) group] and 67 (84%) of the non-uraemic patients with peptic ulcer disease (PU group) received anti-H. pylori therapy. After triple therapy, 32 (94%) from the end-stage renal disease group and 64 (96%) from the peptic ulcer group obtained successful eradication. During the 2-year follow-up, three patients in the end-stage renal disease group were excluded because of the presence of cardiovascular disease and aspirin use in two cases and died of heart failure in one case; two patients in peptic ulcer group refused follow-up. Finally, 29 uraemic and 62 non-uraemic patients had achieved the follow-up. Recurrence of peptic ulcer was more in the end-stage renal disease group than in the peptic ulcer group with intention-to-treat analysis (eight of 32, 25% vs. two of 64, 3%, P = 0.001, OR: 10.0, 95% CI: 1.979-50.540) or per-protocol analysis (eight of 29, 28% vs. two of 62, 3%, P <0.001, OR: 11.4, 95% CI: 2.245-58.168). Conclusions: Peptic ulcer recurrence after H. pylori eradication is higher in end-stage renal disease patients with peptic ulcer than in peptic ulcer patients without renal disease. Factors aside from H. pylori play an important role in peptic ulcer recurrence in end-stage renal disease patients.

UR - http://www.scopus.com/inward/record.url?scp=34548439083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548439083&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2007.03438.x

DO - 10.1111/j.1365-2036.2007.03438.x

M3 - Article

C2 - 17767477

AN - SCOPUS:34548439083

VL - 26

SP - 925

EP - 933

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -